COVID-19 drug development has largely focused on repurposing, either through single
agent or combination therapy 1–5. To date, clinical trial outcomes of the repurposed …

IDentif. AI-x, a clinically actionable artificial intelligence platform, was used to rapidly
pinpoint and prioritize optimal combination therapies against COVID-19 by pairing a …

Objectives We aimed to harness IDentif. AI 2.0, a clinically actionable AI platform to rapidly
pinpoint and prioritize optimal combination therapy regimens against COVID-19. Methods A …

The world was unprepared for coronavirus disease 2019 (COVID-19) and remains ill-
equipped for future pandemics. While unprecedented strides have been made developing …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the
virus that led to the COVID‐19 (Coronavirus Disease 2019) pandemic, has resulted in …

As the global COVID-19 pandemic continues, unabated and clinical trials demonstrate
limited effective pharmaceutical interventions, there is a pressing need to accelerate …

For more than two years, the COVID-19 pandemic has upended the lives of billions of
individuals worldwide leading to disruptions in healthcare, the economy and society at large …

For more than two years, the COVID-19 pandemic has upended the lives of billions of
individualsworldwide leading to disruptions in healthcare, the economy and society at large …

Abstract In 2019/2020, the emergence of coronavirus disease 2019 (COVID‐19) resulted in
rapid increases in infection rates as well as patient mortality. Treatment options addressing …

Nanomedicine-based and unmodified drug interventions to address COVID-19 have
evolved over the course of the pandemic as more information is gleaned and virus variants …